^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EGFRvIII inhibitor

    Related drugs:
    6d
    WAYWIN103: A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Wayshine Biopharm, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tagrisso (osimertinib) • WSD0922
    1m
    A Phase I/II Study to Evaluate EGFR-TKIs in the Treatment of Subjects with Non-Small Cell Lung Cancer (ChiCTR2500108653)
    P1/2, N=78, Not yet recruiting, Shanghai East Hospital; Hangzhou Weiruibao Biopharm Co., LTD.
    New P1/2 trial
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • WSD0922
    2ms
    WAYWIN103: A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC (clinicaltrials.gov)
    P1/2, N=48, Not yet recruiting, Wayshine Biopharm, Inc.
    New P1/2 trial
    |
    Tagrisso (osimertinib) • WSD0922
    2ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Active, not recruiting --> Recruiting | N=43 --> 60 | Trial completion date: Dec 2025 --> Dec 2026
    Enrollment open • Enrollment change • Trial completion date
    |
    GNC-039
    2ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=147 --> 43
    Enrollment closed • Enrollment change
    |
    GNC-039
    3ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=147, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    GNC-039
    3ms
    A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Wayshine Biopharm, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tagrisso (osimertinib) • WSD0922
    3ms
    A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Wayshine Biopharm, Inc. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    WSD0922
    7ms
    A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma (clinicaltrials.gov)
    P1, N=36, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    9ms
    A Study to Assess the Efficacy of WSD0922-FU in Patients with C797S+ Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Wayshine Biopharm, Inc.
    New P2 trial
    |
    Tagrisso (osimertinib) • WSD0922
    9ms
    A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Mar 2025
    Trial completion date • Trial primary completion date
    11ms
    A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Hoffmann-La Roche | N=200 --> 36
    Enrollment change
    |
    EGFRvIII expression